白血病诱导分化剂的研究进展  

Research Progress of Leukemia Induced Differentiation Agents

作　　者：江伟 邓鑫 李海英 黄卫国[1] Wei Jiang;Xin Deng;Haiying Li;Weiguo Huang(Cancer Institute of University of South China, Hengyang Hunan)

机构地区：[1]南华大学肿瘤研究所,湖南衡阳

出　　处：《世界肿瘤研究》2017年第3期75-80,共6页World Journal of Cancer Research

基　　金：中国博士后基金(2012M521528);湖南省教育厅开放创新平台基金(15K109);衡阳市科技项目(2010KJ16);南华大学研究生开放创新课题(2015XCX37)。

摘　　要：诱导分化具有选择性高、副作用小、疗效好等优点。诱导分化机制的研究的深入推动着诱导分化治疗白血病的研究和发展,使其有望成为将来治疗白血病的主要手段。近年来,急性早幼粒细胞白血病的诱导分化治疗已成为目前血液学研究的热点之一,并且国内外对白血病的诱导分化治疗的研究取得了一定的成果。本文对近年来白血病诱导分化的新型诱导分化剂,如:维甲酸类、砷剂、中药类、分子靶向治疗药物类、去甲基化药物类、组蛋白酶去乙酰化药物、miRNA类等的使用与分子机制进行了总结,有利于了解诱导分化剂的研究新进展。Differentiation has the advantages such as highly-selective, low side effect and good curative effect. The further study of differentiation mechanism propels the study and development of treating leukemia by differentiation, and makes it the main method of treating leukemia in the future. In recent years, the differentiation therapy of acute promyelocytic leukemia has become one of the hot points of hematology research, and there has achieved some degree of success in the differentiation therapy of leukemia at home and abroad. This paper summarizes the commonly used and molecular mechanism of differentiation induced agents in recent years, such as, dimension of formic acid, arsenic, traditional Chinese medicine, molecular target drugs, demethylating drugs, acetylating drugs and miRNAs. It is helpful to understand the new progress of differentiation.

关 键 词：白血病 诱导分化 诱导分化剂 

分 类 号：R73[医药卫生—肿瘤]